Literature DB >> 8666028

Fragments of pituitary adenylate cyclase activating polypeptide discriminate between type I and II recombinant receptors.

P Gourlet1, A Vandermeers, M C Vandermeers-Piret, J Rathé, P De Neef, P Robberecht.   

Abstract

Pituitary adenylate cyclase activating polypeptide (PACAP) analogues were tested for their ability to occupy the recombinant selective PACAP receptors (PACAP type I receptor) or the non-selective PACAP-vasoactive intestinal polypeptide (VIP) receptors (PACAP type II, VIP1 and VIP2 receptors) stably transfected and expressed in Chinese hamster ovary (CHO) cells. The synthetic analogues consisted of N- and/or C-terminally shortened peptides. Thus, peptides starting at amino acid 1, 2, 3 or 6 and terminating at amino acid 27, 29, 30, 32 or 38 were compared on the three receptors studied. The shortening of PACAP-(1-38) to PACAP-(1-27) was of little influence. However, in N-terminally deleted peptides the PACAP-38 derivatives were of higher affinity than the PACAP-27 fragments on PACAP type I and PACAP type II, VIP2 receptors but not on PACAP type II, VIP1 receptors. The presence of the sequence 28-32 was in all cases sufficient to reproduce the data obtained with the PACAP-38 analogues. PACAP-(3-32) is able to discriminate the PACAP type II, VIP2 subtype from the other two subtypes, and PACAP-(6-30), PACAP-(6-32) and PACAP-(6-38) can discriminate the PACAP type II, VIP1 receptors from the other two subtypes. These molecules may help in the quantitative detection of receptor subclasses in complex systems when two or more receptor subtypes are found.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8666028     DOI: 10.1016/0014-2999(95)00467-5

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  8 in total

1.  Pituitary adenylate cyclase-activating polypeptide (PACAP) stimulates proliferation of reactive astrocytes in vitro.

Authors:  Tomoya Nakamachi; Keisuke Nakamura; Kanako Oshida; Nobuyuki Kagami; Hiroyoshi Mori; Jun Watanabe; Satoru Arata; Sachiko Yofu; Kimi Endo; Yoshihiro Wada; Motohide Hori; Daisuke Tsuchikawa; Makoto Kato; Seiji Shioda
Journal:  J Mol Neurosci       Date:  2010-06-24       Impact factor: 3.444

Review 2.  Pituitary adenylate cyclase-activating polypeptide receptors in the trigeminovascular system: implications for migraine.

Authors:  Tahlia Sundrum; Christopher S Walker
Journal:  Br J Pharmacol       Date:  2017-10-25       Impact factor: 8.739

3.  CART peptide stimulation of G protein-mediated signaling in differentiated PC12 cells: identification of PACAP 6-38 as a CART receptor antagonist.

Authors:  Yiming Lin; Randy A Hall; Michael J Kuhar
Journal:  Neuropeptides       Date:  2011-08-19       Impact factor: 3.286

4.  Pituitary Adenylate cyclase-activating polypeptide orchestrates neuronal regulation of the astrocytic glutamate-releasing mechanism system xc (.).

Authors:  Linghai Kong; Rebecca Albano; Aric Madayag; Nicholas Raddatz; John R Mantsch; SuJean Choi; Doug Lobner; David A Baker
Journal:  J Neurochem       Date:  2016-03-01       Impact factor: 5.372

5.  Intrahypothalamic pituitary adenylate cyclase-activating polypeptide regulates energy balance via site-specific actions on feeding and metabolism.

Authors:  Jon M Resch; Brian Maunze; Adriana K Gerhardt; Samuel K Magnuson; Kailynn A Phillips; SuJean Choi
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-10-22       Impact factor: 4.310

Review 6.  Targeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis.

Authors:  Yossan-Var Tan; James A Waschek
Journal:  ASN Neuro       Date:  2011-10-06       Impact factor: 4.146

Review 7.  Targeting VIP and PACAP Receptor Signaling: New Insights into Designing Drugs for the PACAP Subfamily of Receptors.

Authors:  Jessica Lu; Sarah J Piper; Peishen Zhao; Laurence J Miller; Denise Wootten; Patrick M Sexton
Journal:  Int J Mol Sci       Date:  2022-07-22       Impact factor: 6.208

8.  PAC1 receptor blockade reduces central nociceptive activity: new approach for primary headache?

Authors:  Jan Hoffmann; Silke Miller; Margarida Martins-Oliveira; Simon Akerman; Weera Supronsinchai; Hong Sun; Licheng Shi; Judy Wang; Dawn Zhu; Sonya Lehto; Hantao Liu; Ruoyuan Yin; Bryan D Moyer; Cen Xu; Peter J Goadsby
Journal:  Pain       Date:  2020-07       Impact factor: 7.926

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.